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Introduction
The incidence of iodine-induced thyrotoxico-
sis after the administration of iodinated contrast 
agent remains low in various patient cohorts 
(0.2% to 1.9% [1, 2]). In patients with coexisting 
subclinical hyperthyroidism and ischemic heart 
disease, however, contrast administration may 
provoke or worsen its clinical condition requiring 
additional endocrinology treatment and clinical 
follow-up after the initial coronary angiography 
(CAG) or percutaneous coronary intervention 
(PCI) [3]. Alternative contrast agents — such as 
gadolinium — replacing iodinated contrast media 
during coronary angiography have been introduced 
previously in small cohorts and case reports to 
avoid nephrotoxicity [4, 5], contrast allergy [6], or 
iodinated-contrast-induced thrombocytopenia [7]. 
The present study, describes a case using a low 
amount of gadolinium for coronary anatomy re-
construction assisting the coronary physiology and 
imaging guided PCI in an elderly patient with acute 
coronary syndrome (ACS) who was simultaneously 
diagnosed with hyperthyroidism.
Case report
An 85-year-old-man, with a history of coro-
nary artery disease (CAD), was referred to the 
documented center with severe ongoing chest 
pain and progressive dyspnea. The patient had 
a prior PCI of the right coronary artery and distal 
left circumflex artery (LCX) performed 1 year prior 
to the current admission to hospital. Additionally, 
the patient had severe peripheral artery disease 
and had undergone multiple prior percutaneous 
transluminal angioplasty of the limbs. Relevant 
coronary risk factors included hypertension, hy-
percholesterinemia and positive family history of 
CAD. The patient was hemodynamically stable, and 
on physical examination no relevant abnormalities 
were detected. Initial laboratory testing revealed 
an elevated level of high sensitive troponin T and 
a normal level of creatine kinase (CK), and creatine 
kinase myocardial band (CK-MB). An electrocar-
diogram showed no relevant ST segment changes, 
and transthoracic echocardiography showed normal 
biventricular function (left ventricular ejection 
fraction of 55%) without significant valve disease. 
The estimated glomerular filtration rate was 
74 mL/min/1.73 m2. Additionally, thyroid stim-
ulating hormone was suppressed, 0.11 µlU/L 
(normal range [NR] 0.27–4.2 µlU/L), whereas T3 
(4.2 pmol/L [NR 3.1–6.8 pmol/L]) and T4 was nor-
mal (16.7 pmol/L [NR 12–22 pmol/L]). Due to the 
possibly underlying subclinical hyperthyroidism,, 
an endocrinological consultation took place which 
revealed the first diagnosis of an ongoing thyroid 
autonomy.
A decision was made to proceed with invasive 
CAG within 72 hours due to intermediate risk, us-
ing low-dose gadolinium for anatomy road mapping. 
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According to a previously reported risk of cardiac ar-
rhythmia and potential hemodynamic instability [8], 
5 mg of metoprolol intravenously (relative beta-1 
selectivity) was administered, defibrillator paddles 
were applied, hemodynamics were continuously 
measured and 1–2 cc first time injections before 
angiography of the left and right coronaries were 
administered (Fig. 1A, B). Coronary physiol-
ogy assessment of fractional flow reserve (FFR) 
(Comet pressure wire, Boston Scientific, Natick, 
Massachusetts, USA) was performed. At maximum 
hyperemia, FFR of the left anterior descend-
ing artery (LAD) was positive (0.77), whereas 
LCX remained functionally insignificant (0.89). 
Thereafter proceeding with PCI, exchanging for 
regular workhorse wire (Sion Blue [Asahii Intecc. 
Nagoya, Japan]) and evaluating the plaque bur-
den, vessel diameter and lesion length (Fig. 1C) 
with intravascular ultrasound (IVUS [Eagle Eye, 
Philips Volcano, Amsterdam, Netherlands]). Two 
drug eluting stents were implanted (2.5 × 12 mm, 
2.75 × 38 mm) in the middle and proximal LAD 
segments. After post-dilation optimal stent expan-
sion was confirmed with control IVUS (Fig. 2). 
Total procedure and fluoroscopy times were 55 
and 10 minutes, respectively. 35 mL of gadolinium 
was used overall. The patient was discharged on 
dual antiplatelet therapy on the 4th day post-PCI. 
Endocrinology control was scheduled to evalu-
ate the thyroid autonomy 2 weeks post-PCI, and 
thiamazole was added to his therapy at discharge.
Discussion
This report illustrates the concept of us-
ing gadolinium to map the coronary anatomy in 
patients with absolute contraindication of using 
conventional iodinated contrast agents, that can 
assist coronary physiology and IVUS for percuta-
neous management of CAD without any iodinated 
contrast use.
The incidence of iodine-induced thyrotoxicosis 
after administration of iodinated contrast agent 
remains low, which mostly results in subclinical 
hyperthyroidism in euthyroid patients regard-
less [1, 2]. Nevertheless, coexisting subclinical 
hyperthyroidism and ischemic heart disease com-
bined with iodinate contrast load after CAG has 
a significant impact on worsening its clinical condi-
tions that may require further treatment, clinical 
follow-up or even re-hospitalization after 1 year 
of CAG/PCI [3]. Bonelli et al. [3] analyzed an 810 
Figure 1. Percutaneous coronary intervention road mapping with intra-arterial gadolinium injection assisting frac-
tional flow reserve coronary physiology assessment and intravascular ultrasound (IVUS) guided stent implantation; 
A, B. Left and right coronary injections with gadolinium; C. IVUS in the left anterior descending artery (LAD); 
D, E. Predilation of the proximal LAD and stenting; F. Distal edge dissection (arrowhead); G. IVUS in the left circumflex 
artery; H. Final result.
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patient cohort without known thyroid diseases who 
had undergone elective CAG. At baseline, 7.2% of 
the patients had hyperthyroidism, that increased 
to 10% after CAG. Independent predictors of hy-
perthyroidism development were baseline free T4 
levels, thyroid nodules, age > 60, male gender, and 
positive family history of thyroid diseases. Despite 
endocrinology follow up and therapy optimization, 
4.2% at 3 months, and 2.5% at one year still had 
hyperthyroidism [3]. Additionally, in elderly pa-
tients, the risk of thyrotoxicosis after CAG with 
underlying thyroid disease is increased [9], and 
can be potentially life threatening, that may lead to 
cardiac tachyarrhythmias, heart failure, pulmonary 
arterial hypertension, pulmonary embolism, and 
cardiomyopathy.
Current guidelines propose early decision 
making on timing of angiography and possible inter-
vention, especially in high-risk patient subgroups 
(elevated cardiac biomarkers at baseline, coexisting 
diabetes mellitus, Global Registry of Acute Coro-
nary Events Risk Score [GRACE score > 140], age 
of 75 ≤ years) with the ultimate goals of reducing 
length of hospital stay, refractory ischemia and mor-
tality. In the present report, the patient’s GRACE 
score was 137, thus current ESC/EACTS guide-
lines indicates invasive treatment in < 72 hours 
(Class I, Level A) [10]. The use of coronary physi-
ology (such as FFR or instant wave-free ratio) has 
been established as a feasible and effective option 
for culprit lesion identification in ACS patients with 
multivessel disease, nevertheless its prognostic 
value remains limited [10]. Moreover, identification 
of the culprit lesion remains challenging in a non-
negligible number of cases with non-ST elevation 
ACS, that may require additional tools — such as 
intravascular imaging — which may further assist 
clinical decision making. Coronary physiology 
combined with intravascular imaging (IVUS in the 
current report) provides a meticulous assessment 
of plaque instability and flow limitation, that has 
also confirmed the need for intervention in the 
aforementioned clinical scenario where conven-
tional iodinated contrast use was not amenable.
Zero contrast and ultra-low contrast use [11] 
during PCIs treatment of complex CAD (such 
as chronic total occlusions) has been previously 
reported. The latter studies, however, reported 
Figure 2. Images of intravascular ultrasound (IVUS) pullbacks performed in the left anterior descending artery (LAD), 
and the left circumflex artery (LCX); A–C. Pullback IVUS images of the LAD; D–F. Pullback IVUS images of the LCX.
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contrast administration (zero contrast PCI was 
defined < 15 mL use of contrast medium), or re-
cent diagnostic angiography was available before 
PCI that served as a road map for these technically 
challenging cases.
The use of gadolinium, as an alternative option 
for replacing iodinated contrast media for coronary 
angiography has been previously introduced [8], 
however its use has been limited due to (a) lower 
image quality, (b) potential adverse events of ven-
tricular tachycardia/fibrillation or hemodynamic 
instability, and (c) its relatively high cost. The 
combination of IVUS and gadolinium has been re-
ported to overcome an adverse reaction of iodinated 
contrast induced thrombocytopenia [7].
Applying gadolinium only for coronary road 
mapping (limiting its use only for the initial and 
final angiography) in combination with coronary 
physiology and IVUS is a potential option to guide 
complex coronary interventions with the benefit 
of fully avoiding using low osmolality iodinated 
contrast agents and hindering nephrotoxicity, ad-
verse allergic reactions or thyrotoxicosis post-PCI. 
Before gadolinium injection, precautionary steps 
are mandatory to avoid adverse cardiac events. 
Herein, protocol included the following steps: 
(a) administration of intravenous beta-blocker, 
(b) applying defibrillator paddles, (c) monitoring 
arterial pressure, (d) avoiding pressure dampening 
of guiding catheters (use of guiding catheters with 
side holes however, could further reduce image 
quality), (e) and adding slow and low amounts of 
test injections.
Conclusions
This report demonstrates the feasibility of 
a concept combining gadolinium, IVUS, and cor-
onary physiology to treat patients with CAD 
and severe coexisting comorbidities that can be 
aggravated by iodinated contrast media.
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